Let's pick a number and say each of the 3 subs are
Post# of 30027
(Total Views: 355)
Posted On: 12/18/2017 7:16:13 PM
Let's pick a number and say each of the 3 subs are worth between $50M & $150M so total of $150M-$450M total. That's anywhere from $1.25 to $3.75 sp with the current OS. Each of the subs compare to a number of the examples the company posted in their various pre-commercial stages. If someone came along and said I'll take everything for $225m, I would think the board would say no. Probably get the same answer at $450M.
Each of the 3 subs are not a one trick pony like some of the bios out there. Elto has 3-4 possible indications. ESS can go after a number of areas even before you get into the whole cosmetic arena. MANF has a dozen indications as a potential. There are enough trials out there and research papers that de-risk this for large investors to come in now similar to the other bios that have raised substantial $. Elto safe. ESS safe. MANF, some bodies apparently can't get enough.
RS have a negative reputation, but 90% of the companies that do it are doing it for the wrong reasons and some have the toxic overhang, that makes it like swimming in a riptide. It's possible a RS won't be necessary, but if it is, I would do it in shortly before releasing some incredible news to springboard this even further on the backs of shorts.
Beyond the $.15 there is a lot of bluesky. I still be holding at $5 as the potential is only greater than two years ago.
Each of the 3 subs are not a one trick pony like some of the bios out there. Elto has 3-4 possible indications. ESS can go after a number of areas even before you get into the whole cosmetic arena. MANF has a dozen indications as a potential. There are enough trials out there and research papers that de-risk this for large investors to come in now similar to the other bios that have raised substantial $. Elto safe. ESS safe. MANF, some bodies apparently can't get enough.
RS have a negative reputation, but 90% of the companies that do it are doing it for the wrong reasons and some have the toxic overhang, that makes it like swimming in a riptide. It's possible a RS won't be necessary, but if it is, I would do it in shortly before releasing some incredible news to springboard this even further on the backs of shorts.
Beyond the $.15 there is a lot of bluesky. I still be holding at $5 as the potential is only greater than two years ago.
(10)
(0)Amarantus Bioscience Holdings (AMBS) Stock Research Links
Scroll down for more posts ▼